🎥 Dans une interview accordée à BFM Business, Frederic Fasano, Directeur Général Adjoint de MaaT Pharma, partage deux moments clés de ces derniers mois, et la stratégie qui guide l'entreprise.
👉 Découvrez l’échange complet avec @Erwan Morice : www.youtube.com/watch?v=XH9l...
@bfmbusiness.bsky.social

📰 We’re thrilled to see our latest achievement covered in CancerNetwork with Roman Fabbricatore highlighting our phase 3 ARES results, confirming MaaT013’s positive benefit/risk profile and its potential as a third-line treatment for GI-aGvHD.
Read the article: www.cancernetwork.com/view/ema-dsm...

📄[Press release] – MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 for the treatment of acute Graft-versus-Host Disease🩸
See the press release: maatpharma.com/march-11-202...

#Cancer #EMA #aGvHD #Pediatric #EMA #Milestone

📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT🩸

maatpharma.com/january-21-2...

#Microbiome #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2

📅 Journée #Microbiotes et #Santé, by LyonBiopôle!
Herve Affagard, CEO and co-founder of MaaT Pharma, and Frederic Fasano, Deputy CEO, will discuss our Positive Phase 3 results in hemato-oncology and comment on the latest advancements in the #microbiota industry.

www.maatpharma.com/january-8-20...
As a former basketball player, the first expression that comes to me now is: nothing but net!
Proud to be part of this team that cures previously non curable patients!